GlassScriptPhysician profile
Keith M Kozeny
NPI 1619971157
$178,467.49
in general payments reported to CMS, 2019-2025
38 companies · $14K in 2025
The $14K reported for 2025 was more than what 90% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $5,413 · 2021: $43K · 2022: $26K · 2023: $50K · 2024: $23K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Food and Beverage: $9,884 · Travel and Lodging: $3,237 · Consulting Fee: $1,750 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,417.00 |
| Food and Beverage | $9,883.59 |
| Travel and Lodging | $3,237.15 |
| Consulting Fee | $1,750.00 |
| Education | $116.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $50,623.34 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $46,964.21 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $32,273.45 | 2019-2024 | Otezla |
| Abbvie INC. | $20,030.35 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $18,289.55 | 2019-2025 | Ilumya |
| Lilly USA, LLC | $2,127.80 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $1,216.45 | 2019-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $1,101.44 | 2019-2025 | |
| Janssen Biotech, INC. | $807.14 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $725.23 | 2019-2025 | Bimzelx, Cimzia |
| Promius Pharma LLC | $500.00 | 2019 | |
| Pfizer INC. | $475.15 | 2019-2025 | |
| Chugai Pharmaceutical Co., LTD. | $422.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $406.90 | 2021-2025 | Sotyktu |
| Incyte Corporation | $369.50 | 2021-2025 | Opzelura |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Kozeny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.